WASHINGTON — Theranos, and the company’s notoriously inaccurate blood tests, could potentially have been stopped earlier if Congress had acted to fix a regulatory loophole.
Lawmakers are weighing now whether it’s better late than never.
Key decisionmakers in Congress are closer than they’ve been in years to revamping the way the government regulates some of the diagnostic tests that patients use to make crucial decisions about their health care.
Create a display name to comment
This name will appear with your comment